Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

J Mansi

Showing results (31-40 of 40) with videos related to

Pageof 4
Sort By:
You have reached the last page of results.This site can display upto 40 results.
Hematological Oncology|November 1, 1990
Decrease in clonogenic tumour cells in bone marrow aspirates from multiple myeloma patients due to the incorporation of cyclophosphamide into treatment with vincristine, adriamycin and methyl prednisoloneJ B Bell, B C Millar, A Montes-Borinaga, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|May 5, 2017
GnRH agonist for protection against ovarian toxicity during chemotherapy for early breast cancer: the Anglo Celtic Group OPTION trialR C F Leonard, D J A Adamson, G Bertelli, et al.
NCI Monographs : a Publication of the National Cancer Institute|January 1, 1986
Prognostic significance of micrometastases in bone marrow in patients with primary breast cancerR C Coombes, U Berger, J Mansi, et al.
Cancer|May 18, 1999
Treatment of nondysgerminomatous ovarian germ cell tumors: an analysis of 69 casesP L Mitchell, N Al-Nasiri, R A'Hern, et al.
British Journal of Cancer|July 2, 1999
Long-term survival after epirubicin, cisplatin and fluorouracil for gastric cancer: results of a randomized trialJ S Waters, A Norman, D Cunningham, et al.
British Journal of Cancer|October 13, 2011
Adjuvant chemotherapy in older women (ACTION) study - what did we learn from the pilot phase?R Leonard, R Ballinger, D Cameron, et al.
British Journal of Cancer|November 28, 2002
Block sequential adriamycin CMF--optimal non-myeloablative chemotherapy for high risk adjuvant breast cancer?D A Cameron, A Anderson, E Toy, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 1, 1997
Randomized trial comparing epirubicin, cisplatin, and fluorouracil versus fluorouracil, doxorubicin, and methotrexate in advanced esophagogastric cancerA Webb, D Cunningham, J H Scarffe, et al.
Breast Cancer Research and Treatment|November 15, 2014
NEOCENT: a randomised feasibility and translational study comparing neoadjuvant endocrine therapy with chemotherapy in ER-rich postmenopausal primary breast cancerC Palmieri, S Cleator, L S Kilburn, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|January 29, 2019
Effects of neratinib on health-related quality of life in women with HER2-positive early-stage breast cancer: longitudinal analyses from the randomized phase III ExteNET trialS Delaloge, D Cella, Y Ye, et al.
Pageof 4

Showing results (31-40 of 40) with videos related to

Sort By:
Pageof 4
You have reached the last page of results.This site can display upto 40 results.
Hematological Oncology|November 1, 1990
Decrease in clonogenic tumour cells in bone marrow aspirates from multiple myeloma patients due to the incorporation of cyclophosphamide into treatment with vincristine, adriamycin and methyl prednisoloneJ B Bell, B C Millar, A Montes-Borinaga, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|May 5, 2017
GnRH agonist for protection against ovarian toxicity during chemotherapy for early breast cancer: the Anglo Celtic Group OPTION trialR C F Leonard, D J A Adamson, G Bertelli, et al.
NCI Monographs : a Publication of the National Cancer Institute|January 1, 1986
Prognostic significance of micrometastases in bone marrow in patients with primary breast cancerR C Coombes, U Berger, J Mansi, et al.
Cancer|May 18, 1999
Treatment of nondysgerminomatous ovarian germ cell tumors: an analysis of 69 casesP L Mitchell, N Al-Nasiri, R A'Hern, et al.
British Journal of Cancer|July 2, 1999
Long-term survival after epirubicin, cisplatin and fluorouracil for gastric cancer: results of a randomized trialJ S Waters, A Norman, D Cunningham, et al.
British Journal of Cancer|October 13, 2011
Adjuvant chemotherapy in older women (ACTION) study - what did we learn from the pilot phase?R Leonard, R Ballinger, D Cameron, et al.
British Journal of Cancer|November 28, 2002
Block sequential adriamycin CMF--optimal non-myeloablative chemotherapy for high risk adjuvant breast cancer?D A Cameron, A Anderson, E Toy, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 1, 1997
Randomized trial comparing epirubicin, cisplatin, and fluorouracil versus fluorouracil, doxorubicin, and methotrexate in advanced esophagogastric cancerA Webb, D Cunningham, J H Scarffe, et al.
Breast Cancer Research and Treatment|November 15, 2014
NEOCENT: a randomised feasibility and translational study comparing neoadjuvant endocrine therapy with chemotherapy in ER-rich postmenopausal primary breast cancerC Palmieri, S Cleator, L S Kilburn, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|January 29, 2019
Effects of neratinib on health-related quality of life in women with HER2-positive early-stage breast cancer: longitudinal analyses from the randomized phase III ExteNET trialS Delaloge, D Cella, Y Ye, et al.
Pageof 4